News

  1. ERT And UCLA Initiate Innovative Pilot Program For Chronically Ill Patients 2/9/2012
    ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study in collaboration with UCLA, an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD).
  2. PHT Corporation Achieves Industry Landmark With 500th ePRO Clinical Trial 1/13/2012
    PHT Corporation cemented its reputation as the dominant player and constant innovator in the Patient Reported Outcomes (PRO) and Electronic Patient Reported Outcomes (ePRO) industry with the announcement of its 500th clinical research trial.
  3. Clinical Research Leaders Discuss Clinical Outcomes, Assessments And Technology At Boston Congress 12/1/2011
    Attendees of PHT’s largest-ever annual PRO and ePRO Congress made it clear that PRO and ePRO are efficient, accurate, and economical methods to collect data within clinical trial research and post-market studies.
  4. ePRO Innovator PHT Corporation Launches Live Chat 24/7 Global Customer Support 11/18/2011
    PHT Corporation continues to define the standard for global ePRO customer support with the launch of the first live chat line in the ePRO industry.
  5. VeriStrat® Results Correlate With Survival Outcomes In Kidney Cancer Patients 10/18/2011
    Data presented at the 10th International Kidney Cancer Symposium being held in Chicago, IL show that the pretreatment blood-based test, VeriStrat, was able to stratify renal cell carcinoma (RCC) patients treated with a combination of two targeted therapies, sunitinib (Sutent®) and erlotinib (Tarceva®), by survival outcomes.
  6. Symfo International And Isis Innovation Announce A Unique Turnkey Solution For Patient Reported Outcomes (PRO) Operations 7/8/2011
    Isis Outcomes, a part of Isis Innovation Ltd, and Symfo are applying their respective areas of expertise to offer Sponsors and CROs a unique service that will help Drug Development/Study Managers to assess and choose the right PRO measure – validating and deploying PRO instruments, and ensuring that the study will meet Regulatory Authorities requirements.